CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:A quality-by-design approach to improve process understanding and optimise the production and quality of CAR-T cells in automated stirred-tank bioreactors.
A quality-by-design approach to improve process understanding and optimise the production and quality of CAR-T cells in automated stirred-tank bioreactors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T 细胞等体外基因修饰细胞免疫疗法,在治疗复发/难治性血液肿瘤方面取得了卓越应答,因此具有显著的临床和商业成果。
然而,这些新疗法的开发和规模化生产仍面临挑战,需要深入理解并优化生产流程,以提升产品质量和产量。本研究采用质量源于设计(QbD)方法,系统考察扩增步骤中的关键工艺参数(CPP)对 CAR-T 关键质量属性(CQA)的影响。研究通过实验设计(DOE)方法分析了多项 CPP,包括激活次数、培养接种密度、种子培养时间和 IL-2 浓度,并评估其对细胞产量、活率、代谢、免疫表型、T 细胞分化、耗竭及 CAR 表达等 CQA 的影响。在 G-Rex 24 多孔板中进行的初步研究显示,与两次激活、7 天种子培养流程相比,单次激活并缩短种子培养至 3 天,可显著提高 CAR-T 产量和质量:细胞产量增加 3 倍,耗竭标志物表达降低 30%,代谢效率也提高。将 G-Rex 多孔板研究确定的 CPP 应用于更大规模、自动化且受控的搅拌罐生物反应器(Ambr 250 High Throughput)后,也观察到类似结果。单次激活和缩短种子培养时间同样显著改善该反应器中的 CAR-T 细胞产量、质量及代谢,验证了小规模研究结果,并深化了工艺认知、推动流程改进。
本研究提供了系统研究 CAR-T 关键工艺参数的方法,结果表明,深入理解工艺可显著改进 CAR-T 生产。
Ex vivo genetically-modified cellular immunotherapies, such as chimeric antigen receptor T cell (CAR-T) therapies, have generated significant clinical and commercial outcomes due to their unparalleled response rates against relapsed and refractory blood cancers.
However, the development and scalable manufacture of these novel therapies remains challenging and further process understanding and optimisation is required to improve product quality and yield. In this study, we employ a quality-by-design (QbD) approach to systematically investigate the impact of critical process parameters (CPPs) during the expansion step on the critical quality attributes (CQAs) of CAR-T cells. Utilising the design of experiments (DOE) methodology, we investigated the impact of multiple CPPs, such as number of activations, culture seeding density, seed train time, and IL-2 concentration, on CAR-T CQAs including, cell yield, viability, metabolism, immunophenotype, T cell differentiation, exhaustion and CAR expression.
Initial studies undertaken in G-Rex 24 multi-well plates demonstrated that the combination of a single activation step and a shorter, 3-day, seed train resulted in significant CAR-T yield and quality improvements, specifically a 3-fold increase in cell yield, a 30% reduction in exhaustion marker expression and more efficient metabolism when compared to a process involving 2 activation steps and a 7-day seed train.
Similar findings were observed when the CPPs identified in the G-Rex multi-well plates studies were translated to a larger-scale automated, controlled stirred-tank bioreactor (Ambr 250 High Throughput) process. The single activation step and reduced seed train time resulted in a similar, significant improvement in CAR-T CQAs including cell yield, quality and metabolism in the Ambr 250 High Throughput bioreactor, thereby validating the findings of the small-scale studies and resulting in significant process understanding and improvements.
This study provides a methodology for the systematic investigation of CAR-T CPPs and the findings demonstrate the scope and impact of enhanced process understanding for improved CAR-T production.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。